市場調査レポート

癌治療の次の波:キナーゼ阻害剤

The Next Wave In Cancer Treatment - Kinase Inhibitors

発行 Kalorama Information 商品コード 258246
出版日 ページ情報 英文 160 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
癌治療の次の波:キナーゼ阻害剤 The Next Wave In Cancer Treatment - Kinase Inhibitors
出版日: 2012年12月04日 ページ情報: 英文 160 Pages
概要

キナーゼ阻害剤の市場は2000年代を通して年平均約17%という力強い成長率を示しています。同市場は確立されつつあり、数種の数十億規模の医薬品も登場していますが、依然として大きな成長の余地があります。今後の5年間においては世界で約200億ドルの規模にまで成長すると予測されており、標的治療薬の成功や癌発症率の増加、新たに承認された治療薬のコスト拡大など、さまざまな要素が引き続き同市場の2桁成長への影響因子となるでしょう。

当レポートでは、癌治療におけるキナーゼ阻害剤の市場について調査分析し、癌および癌の発症に関する概要、主なキナーゼ阻害剤の概要、世界および地域別のキナーゼ阻害剤市場の推移と予測、新たな開発動向、癌市場の動向と影響因子の分析、主要事業者のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 癌とは
    • 癌細胞の生化学
    • 発癌物質の代謝
    • 癌の増殖の原因
      • 環境要因・DNA・RNA
      • 細胞性癌遺伝子
      • 癌抑制遺伝子
  • 癌治療市場の歴史と成長
  • 産業構造
  • 人口動態・統計
    • 世界の癌統計
      • 肺癌
      • 乳癌
      • 結腸癌/直腸癌
    • 米国の癌統計
    • 人口動態
      • 高齢化
  • 寿命と癌
    • 寿命
    • 出生率
  • 主な癌の概要
    • 乳癌
    • 結腸癌
    • 頭頸部癌
    • 腎臓がん
    • 白血病
    • 肝臓癌
    • 肺癌
    • メラノーマ
    • 卵巣癌
    • 膵腺癌
    • 前立腺癌
    • 胃癌

第3章 製品

  • 概要
    • Bosulif (ボスチニブ)
    • Caprelsa (バンデタニブ)
    • Gleevec (イマチニブ)
    • Inlyta (アキシチニブ)
    • Iressa (ゲフィチニブ)
    • Jakafi (ルクソリニチブ)
    • Nexavar (ソラフェニブ)
    • Sprycel (ダサチニブ)
    • Stivarga (レゴラフェニブ)
    • Sutent (スニチニブ)
    • Tarceva (エルロチニブ)
    • Tasigna (ニロチニブ)
    • Tyverb/Tykerb (ラパチニブ)
    • Votrient (パゾパニブ)
    • Xalkori (クリゾチニブ)
    • Zelboraf (ベムラフェニブ)

第4章 市場規模・市場成長

  • 市場サマリー
  • 地域別市場
    • 米国市場
    • 欧州市場
    • 日本市場
    • その他の市場
    • 競合分析

第5章 新たな開発

  • キナーゼ阻害剤のパイプライン
    • 主な開発
      • Afatinib
      • Axitinib
      • Bosutinib
      • Cabozantinib
      • Crizotinib
      • Motesanib
      • Ponatinib
      • Regorafenib
      • Tivozanib
  • 最近のNDAの活動
  • 新たな承認
  • 特許・ジェネリックの開発

第6章 課題・動向

  • イントロダクション
  • 保険と償還
  • 個別化医療
  • 標的癌治療
  • ファーマコゲノミクス
  • 提携・買収・ライセンス契約
    • Amgen
    • アステラス製薬
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly & Co.
    • Johnson & Johnson
    • Merck
    • Novartis
    • Pfizer
  • 患者報告アウトカム(PRO:Patient-Reported Outcome)
  • 癌予防に有望な健康的なライフスタイル
    • 米国の肥満症
    • 米国の肥満率:民族グループによって異なる
    • アルコールの癌発症への影響
  • マーケティング・流通販売動向
  • 地域的動向
    • 米国
    • 欧州
    • 日本
  • 高齢者による臨床試験への参加

第7章 企業プロファイル

  • イントロダクション
  • AstraZeneca plc
  • Bayer
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer, Inc.
  • Roche

付録:主要事業者の所在地

図表

目次
Product Code: KLI7259836

Abstract

This Kalorama Information report - The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including:

  • Breast
  • Colorectal
  • Head/Neck
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Ovarian
  • Pancreatic
  • Prostate
  • Stomach

The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar and unit sales for each product.

The report includes statistical information for relevant cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. The market segments provide an overview, description of kinase inhibitors currently on the market, leading product sales, market estimates and forecasts, and competitive analysis of leading providers. The report also includes a list of products in development and current issues and trends affecting the cancer industry as a whole.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers' level. The base year for data was 2012. Historical data was provided for the years 2007 through 2011, with forecast data provided for 2013 through 2017. Compound annual growth rates (CAGRs) are provided for the 2007-2012, 2012-2017 and 2007-2017 periods for each industry segment covered. Competitive analysis is provided for the year 2012. The forecasted market analysis for 2013-2017 was based on probability of approval and sales of products in late stage development, competitive trends, product marketing, and demographic trends.

The market for kinase inhibitors is heating up. The newer segment has shown strong growth throughout the 2000s with average annual increases of nearly 17%. Although the market is becoming more established and several billion dollar drugs have emerged this segment has enormous room for growth. The potential market is expected to grow to reach almost $20 billion worldwide within the next five years. Several factors continue to influence the double-digit growth this market has experienced, including the continued success of targeted therapy in cancer treatment, rising incidence of cancer, and increased cost for newly approved therapies in the advanced treatment area.

This market report only includes estimates and forecasts for the kinase inhibitor market for cancer indications. For a complete report on the cancer segment see Kalorama Information report Cancer Therapeutics and for an in-depth look at the new cancer vaccine segment see Kalorama Information report Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Tyrosine Kinase Inhibitors (TKIs) Market
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION

  • What is Cancer?
    • Biochemistry of Cancer Cells
    • Carcinogen Metabolism
    • Causes of Cancer Growth
      • Environmental Factors, DNA, RNA
      • Cellular Oncogenes
      • Tumor Suppressor Genes
  • History and Growth of the Cancer Treatment Market
  • Industry Structure
  • Demographics and Statistics
    • Global Cancer Statistics
      • Lung Cancer
      • Breast Cancer
      • Colon/Rectal Cancer
    • Cancer Stats in the United States
    • Demographics
      • Aging Population
  • Life Expectancy and Cancer
    • Life Expectancy
    • Birth Rates
  • Description of Select Cancers
    • Breast Cancer
    • Colorectal Cancer
    • Head and Neck
    • Kidney
    • Leukemia
    • Liver
    • Lung Cancer
    • Melanoma
    • Ovarian Cancer
    • Pancreas
    • Prostate Cancer
    • Stomach Cancer

CHAPTER THREE: PRODUCTS

  • Overview
    • Bosulif (bosutinib)
    • Caprelsa (vandetanib)
    • Gleevec (imatinib)
    • Inlyta (axitinib)
    • Iressa (gefitinib)
    • Jakafi (ruxolitinib)
    • Nexavar (sorafenib)
    • Sprycel (dasatinib)
    • Stivarga (regorafenib)
    • Sutent (sunitinib)
    • Tarceva (erlotinib)
    • Tasigna (nilotinib)
    • Tyverb/Tykerb (lapatinib)
    • Votrient (pazopanib)
    • Xalkori (crizotinib)
    • Zelboraf (vemurafenib)

CHAPTER FOUR: MARKET SIZE AND GROWTH

  • Market Summary
  • Markets by Geographical Segments
    • U.S. Market
    • Europe Market
    • Japan Market
    • ROW Market
    • Competitive Analysis

CHAPTER FIVE: NEW DEVELOPMENTS

  • The Pipeline for Kinase Inhibitors
    • Significant Developments
      • Afatinib
      • Axitinib
      • Bosutinib
      • Cabozantinib
      • Crizotinib
      • Motesanib
      • Ponatinib
      • Regorafenib
      • Tivozanib
  • Recent NDA Activity
  • New Approvals
  • Patent Activity and Generic Development

CHAPTER SIX: ISSUES AND TRENDS

  • Introduction
  • Insurance and Reimbursement Issues
  • Personalized Medicine
  • Targeted Cancer Therapy
  • Pharmacogenomics
  • Alliances Acquisitions and Licensing Agreements
    • Amgen
    • Astellas
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly & Co.
    • Johnson & Johnson
    • Merck
    • Novartis
    • Pfizer
  • Patient-Reported Outcomes
  • Healthy Lifestyles Continue to Show Promise for Cancer Prevention
    • Obesity in the U.S.
    • U.S. Obesity Rates Differ Among Ethnic Groups
    • Alcohol's Affect on Cancer Incidence
  • Marketing and Distribution Trends
  • Geographical Trends
    • United States
    • Europe
    • Japan
  • Elderly Clinical Trial Involvement

CHAPTER SEVEN:COMPANY PROFILES

  • Introduction
  • AstraZeneca plc
  • Bayer
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline
  • Novartis
  • Pfizer, Inc.
  • Roche

APPENDIX:MAJOR COMPETITORS' ADDRESSES

CHAPTER ONE: EXECUTIVE SUMMARY

  • Figure 1-1: Sales of Kinase Inhibitor Products, 2012
  • Figure 1-2: World Cancer Kinase Inhibitor Market, 2007-2017
  • Table 1-1: World Cancer Kinase Inhibitor Market, 2007-2017
  • Figure 1-1: World Cancer Kinase Inhibitor Market, 2007-2017 w/ Growth Trend

CHAPTER TWO: INTRODUCTION

  • Table 2-1: Viruses Associated with Cancer in Humans
  • Figure 2-1: Approved Cancer Therapies in the United States by Primary Indication
  • Figure 2-2: Approved Kinase Inhibitors for Cancer Treatment in the United States by Original Indication*
  • Table 2-2: Total Cancer Incidence by Gender and Country, 2010 Estimates
  • Figure 2-3: Cancer Incidence by Gender and Country, 2010 Estimates
  • Table 2-3: World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, all races, both genders
  • Figure 2-4: Estimated and Projected World Cancer Incidence by
  • Selected Types of Cancer, 2010 and 2020
  • Table 2-4: Most Common Cancer by Region and Gender
  • Table 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates
  • Figure 2-5: United States: Total Cancer Incidence by Gender, 2012 Estimates
  • Table 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates
  • Figure 2-6: United States: Total Cancer Deaths by Gender, 2012 Estimates
  • Table 2-7: World Population by Selected Geographical Region, 2010 - 2050
  • Figure 2-7: World Population by Selected Geographical Region, 2010 - 2050
  • Table 2-8: Percent Population Over 65 by Year and Region, 2010-2050
  • Figure 2-8: Estimated World Population by Age, 2010 and 2050
  • Table 2-9: Average Life Expectancy in Years by Country 1980 and 2011
  • Figure 2-9: Average Life Expectancy in Years by Country 1980 and 2011
  • Table 2-10: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2009
  • Table 2-11: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2009
  • Table 2-10: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
  • Figure 2-12: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
  • Table 2-11: Types of Leukemia
  • Table 2-12: Types of Primary Lung Cancer
  • Table 2-13: Malignant Conditions of the Skin

CHAPTER THREE: PRODUCTS

  • Table 3-1: Cancer Indicated Kinase Inhibitor Approvals by Year
  • Figure 3-1: Table 3-2: Leading Products by Sales, 2010 and 2012

CHAPTER FOUR: MARKET SIZE AND GROWTH

  • Table 4-1: World Cancer Kinase Inhibitor Market, 2007-2017
  • Figure 4-1: World Cancer Kinase Inhibitor Market, 2007-2017
  • Table 4-2: World Cancer Kinase Inhibitor Market
  • Figure 4-2: World Cancer Kinase Inhibitors Market
  • Table 4-3: U.S. Kinase Inhibitor Products by Sales, 2012
  • Figure 4-3: U.S. Kinase Inhibitor Products by Sales, 2012
  • Table 4-4: Europe Kinase Inhibitor Products by Sales, 2012
  • Figure 4-4: Europe Kinase Inhibitor Products by Sales, 2012
  • Figure 4-5: World Cancer Kinase Inhibitor Market
  • Figure 4-6: World Cancer Kinase Inhibitor Market
  • Figure 4-7: World Cancer Kinase Inhibitor Market
  • Table 4-5: Top 5 Suppliers: Cancer Kinase Inhibitor Market - Shares by Market Revenues, 2012
  • Figure 4-8: Top 5 Suppliers: Cancer Kinase Inhibitor Market - Shares by Market Revenues, 2012

CHAPTER FIVE: NEW DEVELOPMENTS

  • Table 5-1: Developments in Kinase Inhibitors, Selected Projects
  • Figure 5-1: Registration and Phase III Compounds in Development for Major Indications, Distribution Estimates
  • Table 5-2: Recent NDA Activity: January 2011-October 2012
  • Table 5-3: Select New Approvals (NCE, Indications, Dosage, Formulations) January 2010-October 2012
  • Table 5-4: Patent Data for Kinase Inhibitors

CHAPTER SIX: ISSUES AND TRENDS AFFECTING THE CANCER MARKET

  • Table 6-1: Obesity Rates by U.S. State, 2011

CHAPTER SEVEN: COMPANY PROFILES

  • Figure 7-1: Cancer Kinase Inhibitor Development for Leading Companies
Back to Top